RTW Investments LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
RTW Investments LP
CRD #153232
SEC #801-78183
CIK #0001493215
AUM 14.14 B (2026-03-30)
Employees 70 (50% Investors, 0% Brokers)
Fees
Minimum
Phone646-597-6980
Address40 10th Avenue
New York, NY 10014
Source [IAPD] [EDGAR] [Website] [LinkedIn] [Instagram]
Total AUM ($B)
151296302010201520212027
In the News
Thu, 23 Jul 2026 RTW Investments swaps Allurion (ALUR) stock into pre-funded warrants — Stock Titan
Fri, 15 May 2026 RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS) — Stock Titan
Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure]
Item 5: Fees and Compensation

Detailed information with respect to how RTW is compensated for the advisory services it
provides is contained within the offering document for each Fund. Generally, RTW is
compensated by the receipt of management fees and certain performance-based fees as
described below. Prospective investors should carefully review the offering documents for the
relevant investment vehicle prior to making an investment.

As compensation for its services, RTW will generally receive a management fee in accordance
with the offering documents. RTW will receive from the Flagship Fund an annual management
fee of 2.00% or 1.25% of each Limited Partner’s Basic Capital Account and any Designated
Capital Accounts (as those accounts are defined in the offering documents) to be collected
on a monthly basis in advance (0.167% or 0.104%, respectively, to be collected per month).

RTW will receive from the Innovation Fund an annual administrative allocation of 2.00% or1.25%
of the net asset value of each Limited Partner’s Basic Capital Account and any Designated
Capital Accounts (as those accounts are defined in the offering documents) to be collected

RTW Investments, LP                                                          Form ADV Part 2A
on a quarterly basis as of the last day of the fiscal quarter (0.50% or 0.3125%, respectively, to
be collected per quarter), provided there were net profits equal to the applicable
administrative allocation during that quarter. If all or a portion of the administrative allocation
for any quarter has not been allocated due to insufficient net profits, the unallocated portion
of such administrative allocation (the “Unallocated Amount”) will be rolled over and
added to the administrative allocation for the following quarter and any future quarter. If
there were a net loss for each of the immediately preceding four consecutive quarters, then
the Unallocated Amount shall be reduced by the administrative allocation that was not made
in respect of each of those four preceding consecutive quarters. For the avoidance of doubt,
the administrative allocation is not subject to a loss carryforward and will be made even if
the Innovation Fund is below its high-water mark.

RTW will receive management fees from the Royalty Fund in an annual amount equal to (i)
during the investment period which begins after the first investor closing (“Initial Closing”)
and will end on the third anniversary of the Initial Closing (“the Investment Period”), the
product of 2.0% and “Net Invested Capital” (generally, with respect to each investment, the
lesser of cost and fair market value), and (ii) after the Investment Period, the product of 2.0% and
Net Invested Capital.

RTW will receive from the Biotech Opportunities Fund an annual management fee of
1.25% of the net asset value to be collected on a monthly basis in advance (0.104%, to be
collected per month). The monthly management fee for the Flagship Fund and the Biotech
Opportunities Fund, the quarterly administrative allocation for the Innovation Fund, and
the quarterly management fee for the Royalty Fund will be drawn from the Flagship Fund,
the Biotech Opportunities Fund, the Innovation Fund, and the Royalty Fund respectively,
and paid or allocated to RTW.

Management fees are deducted from the relevant Funds’ account by the applicable Funds’
administrator. At its sole discretion, RTW may elect to waive or modify the management
fee or administrative allocation for investors who are members, partners, employees or
affiliates of RTW, relatives of such persons and for certain strategic investors.

RTW is responsible for all overhead expenses, including office rent; furniture and fixtures;
stationery; secretarial/internal administrative services; salaries and bonuses; entertainment
expenses; employee insurance and payroll taxes. All other expenses are paid by the Funds and
include the management fees; expenses incurred in connection with identifying, evaluating,
researching (including attending related industry conferences), structuring and negotiating
proposed Fund investments (including those that are not ultimately consummated by the
Funds), as well as research related travel and associated meals and entertainment; expenses
associated with investment monitoring, such as meetings with portfolio company management
teams (including meetings of the board of directors); the Funds’ organizational expenses; Fund-
related compliance expenses; valuation expenses; brokers’ or other third-party deal sourcers’
fees and expenses (including retainers and similar fees and advancement of expenses), sales
commissions and fees, commitment fees, non-refundable deposits and costs and expenses
incurred in connection with the acquisition or disposition of actual or potential investments
(whether or not consummated); principal and interest and fees, commissions, costs and
expenses and other amounts payable related to or arising from any indebtedness, any
subscription facility, guarantees or hedging activities of the Funds (including in connection
with the negotiation and establishment of the relevant subscription facility, credit support or
other relevant arrangements); costs related to the operations of the Funds, including, without
limitation, fees, costs and expenses of any third-party administrator, software, experts,
appraisers, custodians, outside counsel, advisors, bona fide consultants, accountants, auditors,
tax return preparers and other professionals, including expenses associated with the
preparation of the financial statements and tax returns and other tax filings of the Funds and
its subsidiaries; expenses related to organizing, maintaining, operating, restructuring, winding
up, liquidating and/or dissolving entities through or in which investments may be made
(including any general partner (or equivalent) of such entities); taxes and other governmental
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure]
Item 7: Types of Clients

The Firm’s clients are the Funds. The initial and additional subscription minimums for each
Fund are disclosed in the offering documents which are provided to investors or prospective
investors of the Funds.
Sector Form 13F Holdings Value ($B)
Synta Pharmaceuticals Corp 1.0
Insmed Inc 0.8
Protagonist Therapeutics Inc 0.5
PTC Therapeutics Inc 0.5
Argenx SE 0.5
CG Oncology Inc 0.5
Celcuity Inc 0.3
BCTG Acquisition Corp 0.3
Erasca Inc 0.3
Natera Inc 0.2
View All
Holdings by Sector ($B)
151296302015201920232027
Type Form D Funds Date Sold AUM
PE 4010 Royalty Investments ICAV [2024-03-28] 111.8 M 284.4 M
Offered $111,770,000 · Filed 2025-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration More than one year · Commission $56,000 · Revenue Decline to Disclose
HF RTW Special Purpose Fund II LLC [2019-11-04] 16.4 M 73.8 M
Filed 2019-11-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF RTW Special Purpose Fund I LLC 2017-03-29 65.8 M
HF RTW Innovation Master Fund Ltd [2016-03-30] 918.4 M 5,465.0 M
Filed 2025-07-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF RTW Innovation Offshore Fund Ltd 2016-03-30
HF RTW Innovation Onshore Fund LP 2016-03-30 11.0 M
HF RTW Master Fund Ltd [2012-10-31] 1,985.8 M 7,355.5 M
Filed 2025-07-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $8,900,000 · Net Assets Decline to Disclose
HF RTW Offshore Fund One Ltd [2012-10-31] 1.5 M 183.9 M
Offered $1,453,279 · Filed 2022-05-02 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $10,000 · Duration One year or less · Revenue Decline to Disclose
HF RTW Onshore Fund One LP [2012-10-31] 1,584.4 M 290.0 M
Filed 2025-07-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $13,700,000 · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 10 14.1
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 10 14.1
By Discretionary
Discretionary 10 14.1
Non-Discretionary 0 0.0
Total 10 14.1
By Non-United States Persons
Non-United States Persons 6.8
United States Persons 7.4
Total 10 14.1
Form D Directors Role # Filings # Firms 2011 - 2026
Peter O'Leary Director 10 3
Jeffrey Brotman Director 6 3
Roderick Wong Executive Officer 14 2
Ef Capital Management Executive Officer 11 2
Rtw Fund Group GP LLC Executive Officer, Promoter 6 2
Rtw Investments LP Promoter 3 2
Agemian Patrick Director 2 2
Nathan Pelsma Director 2 2
4010 Royalty Fund GP LLC Promoter 2 2
Dermot Hanley Director 2 2
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0001493215]
3 [0001493215]
4 [0001493215]
SC 13D [0001493215]
SC 13G [0001493215]
Form 13D/13G Filer Form 13D/13G Subject Filed
RTW Investments LP iRhythm Holdings Inc [2026-05-15]
RTW Investments LP Tango Therapeutics Inc [2026-05-15]
RTW Investments LP Candel Therapeutics Inc [2026-05-15]
RTW Investments LP Celcuity Inc [2026-05-15]
RTW Investments LP Century Therapeutics Inc [2026-05-15]
RTW Investments LP CG Oncology Inc [2026-05-15]
RTW Investments LP Erasca Inc [2026-05-15]
RTW Investments LP Kalaris Therapeutics Inc [2026-02-17]
RTW Investments LP Zai Lab Ltd [2026-02-17]
RTW Investments LP Apellis Pharmaceuticals Inc [2026-02-17]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI54930058PPKTSERDV366
Form 3/4/5 Subject 2011 - 2026
Health Sciences Acquisitions Corp 2
RTW Investments LP
Wong Roderick
Kailera Therapeutics Inc
Allurion Technologies Inc
RTW Innovation Master Fund Ltd
RTW Master Fund Ltd
Rocket Pharmaceuticals Inc
CARGO Therapeutics Inc
Renovacor Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-11-12 Grant 991,544 $1.67 1,655,878
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-11-12 Grant 96,896 $1.67 161,816
Allurion Technologies Inc ALUR
Warrant (Right to Buy) · derivative
2025-11-12 Grant 767,848
Allurion Technologies Inc ALUR
Warrant (Right to Buy) · derivative
2025-11-12 Grant 991,544
Allurion Technologies Inc ALUR
Warrant (Right to Buy) · derivative
2025-11-12 Grant 96,896
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-11-12 Grant 767,848 $1.67 1,282,306
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-11-05 Conversion 822,722 $3.35 2,756,119
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-11-05 Conversion 37,863 $3.35 126,841
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-11-05 Conversion 631,954 $3.35 2,117,046
Allurion Technologies Inc ALUR
Convertible Note · derivative
2025-11-05 Grant $126,839.00
Allurion Technologies Inc ALUR
Convertible Note · derivative
2025-11-05 Conversion $2,117,044.00
Allurion Technologies Inc ALUR
Convertible Note · derivative
2025-11-05 Grant $2,117,044.00
Allurion Technologies Inc ALUR
Convertible Note · derivative
2025-11-05 Conversion $2,756,117.00
Allurion Technologies Inc ALUR
Convertible Note · derivative
2025-11-05 Grant $2,756,117.00
Allurion Technologies Inc ALUR
Convertible Note · derivative
2025-11-05 Conversion $126,839.00
Health Sciences Acquisitions Corp 2 OBIO
Pre-Funded Warrants (Right to Buy) · derivative
2025-08-04 Buy 3,636,363 $2.75 9,999,998
Health Sciences Acquisitions Corp 2 OBIO
Common Stock
2025-04-30 Buy 49,900 $2.99 149,201
Health Sciences Acquisitions Corp 2 OBIO
Common Stock
2025-04-29 Buy 50,000 $2.53 126,500
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-04-16 Conversion 822,722 $3.35 2,756,119
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
2025-04-16 Conversion 37,863 $3.35 126,841
showing 20 of 151 most recent transactions
Comparable Firms State AUM
Blackstone Ireland Limited
15.19 B
Abry Partners II LLC
MA 14.90 B
Napier Park Global Capital US LP
NY 14.57 B
BSP NY LLC
NY 14.24 B
SRS Investment Management LLC
NY 13.92 B
Dynasty Wealth Management LLC
FL 13.88 B
LibreMax Capital LLC
NY 13.87 B
Avoro Capital Advisors LLC
NY 13.55 B
Eagle Point Credit Management LLC
CT 13.24 B
Post Advisory Group LLC
CA 13.03 B
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com